An Assessment of Rapid Streptococcal Tests in Community Clinics in Israel
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00535093|
Recruitment Status : Completed
First Posted : September 26, 2007
Last Update Posted : May 4, 2010
There is a large over-use of antibiotics in family medicine, especially in upper respiratory tract infections.
This study is designed to determine if the use of rapid Streptococcal tests in primary care clinics can lower the rate of antibiotic use while not missing bacterial infections.
|Condition or disease||Intervention/treatment||Phase|
|Pharyngitis Streptococcus Pyogenes Infection Streptococcus Pyogenes Identification||Device: rapid streptococcal testing||Not Applicable|
Pharyngitis is a clinical diagnosis which requires antibiotic treatment only if caused by group A Streptococcus (GAS).
However, it is impossible to identify by clinical signs alone those patients whose symptoms are caused by this pathogen.
Diagnosis demands a throat culture, which requires at least 24 hours to rule in infection and 48 hours to rule it out.
Rapid Streptococcal tests (RST) based on antigen identification have been in use for over 10 years. These allow determination of the presence of GAS within 10 minutes using tests designed for point of care use.
While the specificity of these tests is generally reported as high (90-95%), the sensitivity is quoted at between 60% and 90% , depending on author affiliation, place of testing and type of test.
Various protocols have been put forward, these combine clinical signs (Centor criteria) with RST or throat cultures in order to lower antibiotic over-use.
These protocols are often under-used by primary physicians, even when RSTs are available.
Clalit health services, the largest HMO in Israel, has decided to evaluate all the RSTs available in the country in community clinic settings in order to determine the feasibility of adopting these tests to improve clinical care.
The sensitivity, specificity and ease-of-use will be assessed in 25 clinics in various settings (urban and rural). Gold standard will be a standard throat culture processed in the district laboratory.
The effect of point-of-care testing will be estimated by requiring physicians to decide on antibiotic use before receiving the result of the RST. (They will be free to change this decision after the test).
Clinics were selected by number of throat cultures sent in previous years. The number of patients was determined using the positivity rates of 2005. The results of this study will enable us to estimate the benefit and cost of adopting RSTs, and to determine in which situations they will be most efficacious.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||7000 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Comparison of Available Rapid Streptococcus A Tests in Community Clinics in Israel: Accuracy, Ease of Use and Acceptability.|
|Study Start Date :||October 2007|
|Actual Primary Completion Date :||July 2009|
|Actual Study Completion Date :||July 2009|
No Intervention: 1
All patients fulfilling inclusion criteria will be evaluated for GAS infection using both a rapid streptococcus test and also a standard throat culture
Device: rapid streptococcal testing
Each patient will have both RST and standard throat culture performed. Final diagnosis and treatment will be determined by throat culture
- sensitivity of RST specificity of RST [ Time Frame: 3-4 months ]
- ease of use effect on antibacterial prescribing [ Time Frame: 3-4 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00535093
|Clalit Health Services|
|Principal Investigator:||Ian N Miskin, MD||Clalit Health Services, Jerusalem district|